Author:
Yoneda Kazue,Tanaka Fumihiro
Reference23 articles.
1. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–48. https://doi.org/10.3389/fonc.2019.00740.
2. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–7. https://doi.org/10.1158/1078-0432.CCR-12-2246.
3. Wang J, Chang S, Li G, Sun Y. Application of liquid biopsy in precision medicine: opportunities and challenges. Front Med. 2017;11:522–7. https://doi.org/10.1007/s11684-017-0526-7.
4. Yoneda K, Tanaka F. Molecular diagnosis and targeting for lung cancer. In: Shinomiya N, Kataoka H, Shimada Y, editors. Molecular diagnosis and targeting for thoracic and gastrointestinal malignancy. Singapore: Springer; 2018. p. 1–32.
5. Yoneda K, Imanishi N, Ichiki Y, Tanaka F. A liquid biopsy in primary lung cancer. Surg Today. 2019;49:1–14. https://doi.org/10.1007/s00595-018-1659-2.